Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real‐World Retrospective Cohort Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.71333 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Muhammad Ali Khan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Symptom Assessment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Symptom management in myeloproliferative neoplasms (MPN) remains challenging despite advancements in disease‐directed therapies. This study assessed the impact of demographic, clinical, laboratory and treatment‐related variables on total symptom scores (TSS) and individual symptom scores in patients with polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).
Methods
A cohort of 553 patients (PV: 200; ET: 190; MF: 163) was identified through a retrospective chart review. Symptom scores, demographic information and clinical variables were captured at the time of the first TSS assessment. Laboratory results within 1 month and treatment information within 90 days prior to the symptom assessment were captured. Univariable linear regression, followed by multivariable regression analyses using a robust variance estimator were performed, with a p value < 0.05 indicating a significant association.
Results
MF patients experienced the highest symptom burden and fatigue was the most reported symptom across all MPN subtypes. In PV, depression ( β : 10.53; p = 0.001) was associated with a higher TSS whereas older age (−0.17; 0.01) and higher hemoglobin (−1.24; 0.003) were associated with a lower TSS. In ET, depression ( β : 14.19; p < 0.001) was associated with a higher TSS, whereas in MF, depression (12.28; < 0.001) and higher WBC count (0.22; 0.02) were associated with a higher TSS. Depression and non‐White race in PV, depression in ET, and depression, low hemoglobin, and higher WBC count in MF were associated with multiple symptoms.
Conclusions
Integrating depression screening and management and optimizing hematologic parameters alongside disease‐directed therapy is crucial to improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, Arizona, USA.
ORCID-Profile: Muhammad Ali Khan, Cecilia Y Arana Yi, Jeanne M Palmer
Zitieren
APA
Khan, M. A., Naqvi, S. A. A., Camoriano, J. K., Arana Yi, C. Y., Andres, J. T., Blocher, J. L., Kosiorek, H. E., Riaz, I. B., & Palmer, J. M. (2025). Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real‐World Retrospective Cohort Study. Cancer Medicine. https://doi.org/10.1002/cam4.71333
Vancouver
Khan MA, Naqvi SAA, Camoriano JK, Arana Yi CY, Andres JT, Blocher JL, et al. Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real‐World Retrospective Cohort Study. Cancer Medicine. 2025. doi:10.1002/cam4.71333
BibTeX
@article{Khan2025,
author = {Khan, Muhammad Ali and Naqvi, Syed Arsalan Ahmed and Camoriano, John K and Arana Yi, Cecilia Y and Andres, Jennifer T and Blocher, Joshua L and Kosiorek, Heidi E and Riaz, Irbaz Bin and Palmer, Jeanne M},
title = {Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real‐World Retrospective Cohort Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71333}
}
EUVIMED